|
Gene: C19orf66 |
Gene summary for C19ORF66 |
Gene summary. |
Gene information | Species | Human | Gene symbol | C19orf66 | Gene ID | 55337 |
Gene name | shiftless antiviral inhibitor of ribosomal frameshifting | |
Gene Alias | C19orf66 | |
Cytomap | 19p13.2 | |
Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q9NUL5 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55337 | C19orf66 | P1T-E | Human | Esophagus | ESCC | 2.79e-11 | 6.65e-01 | 0.0875 |
55337 | C19orf66 | P2T-E | Human | Esophagus | ESCC | 2.89e-17 | 4.41e-01 | 0.1177 |
55337 | C19orf66 | P4T-E | Human | Esophagus | ESCC | 2.80e-12 | 4.18e-01 | 0.1323 |
55337 | C19orf66 | P5T-E | Human | Esophagus | ESCC | 5.18e-22 | 4.94e-01 | 0.1327 |
55337 | C19orf66 | P8T-E | Human | Esophagus | ESCC | 9.69e-22 | 4.94e-01 | 0.0889 |
55337 | C19orf66 | P9T-E | Human | Esophagus | ESCC | 2.27e-23 | 6.63e-01 | 0.1131 |
55337 | C19orf66 | P10T-E | Human | Esophagus | ESCC | 3.41e-14 | 2.82e-01 | 0.116 |
55337 | C19orf66 | P11T-E | Human | Esophagus | ESCC | 2.24e-22 | 1.06e+00 | 0.1426 |
55337 | C19orf66 | P12T-E | Human | Esophagus | ESCC | 1.02e-11 | 3.35e-01 | 0.1122 |
55337 | C19orf66 | P15T-E | Human | Esophagus | ESCC | 1.15e-10 | 2.96e-01 | 0.1149 |
55337 | C19orf66 | P16T-E | Human | Esophagus | ESCC | 2.02e-16 | 2.02e-01 | 0.1153 |
55337 | C19orf66 | P17T-E | Human | Esophagus | ESCC | 2.66e-10 | 7.38e-01 | 0.1278 |
55337 | C19orf66 | P19T-E | Human | Esophagus | ESCC | 1.38e-08 | 8.14e-01 | 0.1662 |
55337 | C19orf66 | P20T-E | Human | Esophagus | ESCC | 5.79e-22 | 6.42e-01 | 0.1124 |
55337 | C19orf66 | P21T-E | Human | Esophagus | ESCC | 3.48e-19 | 5.07e-01 | 0.1617 |
55337 | C19orf66 | P22T-E | Human | Esophagus | ESCC | 1.22e-13 | 3.01e-01 | 0.1236 |
55337 | C19orf66 | P23T-E | Human | Esophagus | ESCC | 1.07e-28 | 7.59e-01 | 0.108 |
55337 | C19orf66 | P24T-E | Human | Esophagus | ESCC | 3.25e-20 | 5.97e-01 | 0.1287 |
55337 | C19orf66 | P26T-E | Human | Esophagus | ESCC | 7.96e-22 | 4.06e-01 | 0.1276 |
55337 | C19orf66 | P27T-E | Human | Esophagus | ESCC | 8.18e-21 | 4.67e-01 | 0.1055 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Stomach | WIM | |
Stomach | SIM | |
Liver | NAFLD | |
Liver | Cirrhotic | |
Liver | HCC |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C19orf66 | SNV | Missense_Mutation | c.131G>T | p.Arg44Leu | p.R44L | Q9NUL5 | protein_coding | deleterious(0.04) | possibly_damaging(0.501) | TCGA-BH-A1FC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
C19orf66 | SNV | Missense_Mutation | c.145N>A | p.Gly49Arg | p.G49R | Q9NUL5 | protein_coding | tolerated(0.37) | benign(0.352) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
C19orf66 | SNV | Missense_Mutation | rs370905686 | c.412N>T | p.Arg138Cys | p.R138C | Q9NUL5 | protein_coding | tolerated(0.05) | benign(0.01) | TCGA-QG-A5Z2-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
C19orf66 | deletion | Frame_Shift_Del | c.566delC | p.Pro189ArgfsTer67 | p.P189Rfs*67 | Q9NUL5 | protein_coding | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |||
C19orf66 | insertion | Frame_Shift_Ins | rs750276509 | c.560_561insC | p.Arg190AlafsTer57 | p.R190Afs*57 | Q9NUL5 | protein_coding | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
C19orf66 | deletion | Frame_Shift_Del | c.561delN | p.Pro189ArgfsTer67 | p.P189Rfs*67 | Q9NUL5 | protein_coding | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |||
C19orf66 | deletion | Frame_Shift_Del | c.566delC | p.Pro189ArgfsTer67 | p.P189Rfs*67 | Q9NUL5 | protein_coding | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |||
C19orf66 | deletion | Frame_Shift_Del | c.561delN | p.Pro189ArgfsTer67 | p.P189Rfs*67 | Q9NUL5 | protein_coding | TCGA-D5-6540-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |||
C19orf66 | SNV | Missense_Mutation | novel | c.406C>T | p.Arg136Trp | p.R136W | Q9NUL5 | protein_coding | deleterious(0.03) | possibly_damaging(0.877) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
C19orf66 | SNV | Missense_Mutation | novel | c.772G>T | p.Gly258Cys | p.G258C | Q9NUL5 | protein_coding | deleterious(0.02) | benign(0.065) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |